[212Pb]Pb-Mp0712, [203Pb]Pb-Mp0712
Small Cell Lung Cancer (Sclc), Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma Of The Lung (Lcnec), Extrapulmonary Neuroendocrine Carcinoma (Ep-Nec), Gastroenteropancreatic Nec (Gep Nec), Nec Of The Bladder, Other Dll3 Expressing Epnec
Phase I/II
Recruiting
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Nov 10, 2025
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Molecular Partners AG (6ML) have in its pipeline
6ML is currently developing the following drugs: [212Pb]Pb-Mp0712, [203Pb]Pb-Mp0712. These drug candidates are in various stages of clinical development as the company works toward FDA approval.